Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eteplirsen in Ambulant Subjects With Duchenne Muscular Dystrophy
NCT01396239Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jul 2011
- Primary completion
- Feb 2012
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Jul 2011; status: completed.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01396239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396239.